Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Bronchial Asthma | Research article

Profile and preliminary results of Iranian sub cohort chronic obstructive pulmonary disease (COPD) in Shahrekord PERSIAN cohort in southwest Iran

Authors: Fatemeh Zeynab Kiani, Ali Ahmadi, Akbar Soleymani Babadi, Hamid Rouhi

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

Chronic obstructive pulmonary disease (COPD) is a chronic and complex respiratory disorder associated with airflow limitation and increased inflammatory response of the lungs to harmful particles. The purpose of this original study was to describe the results and profile of the Shahrekord Prospective Epidemiological Research Studies in IrAN (PERSIAN) regarding COPD in southwestern Iran.

Methods

This study of asthma and respiratory diseases is a subcohort of the more extensive cohort study, i.e., Shahrekord PERSIAN cohort, a population-based prospective study on people aged 35–70 years in southwestern Iran (n = 10,075). The sample size of the subcohort was 8500 people. Annual follow-ups (person-year) of the cohort were designed to be conducted up to 2036. The instruments to collect data on various exposures were derived from the questionnaires previously developed in extensive multinational studies (occupational exposures, smoking, housing status, and fuel consumption, history of respiratory and chronic diseases, comorbidity, etc.). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the lower limit of normal (LLN) spirometric criteria were used to confirm COPD diagnosis.

Results

The response rate was 93.85%. The mean age of the participants was 49.48 ± 9.32; 47.9% were male, and 52.9% were female; nearly 16% of the population was current smokers; the fuel used by most of the participants for heating the house and cooking was gas. The most common comorbidity among participants was dyslipidemia; 30% of people have three or more comorbidities. According to GOLD and LLN criteria, the Prevalence of COPD was 3.6% and 8.4%, respectively. 4.3% of the participants had a history of chronic lung disease. The group of subjects with COPD had higher mean age, fewer years of schooling, a higher percentage of smokers with a smoking history of 10 or more pack years. 4.6% of patients had a history of chronic lung disease, 17.6% had a history of asthma in childhood, and 5.2% had a family history of respiratory and pulmonary diseases.

Conclusion

Epidemiological research is necessary to create an appropriate framework to fight COPD. This framework requires a better description of men and women at risk of developing COPD and describing people with early-stage illnesses.
Literature
1.
go back to reference Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.CrossRef Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.CrossRef
2.
go back to reference Garcia-Gordillo MA, Collado-Mateo D, Olivares PR, Adsuar JC, Merellano-Navarro E. A cross-sectional assessment of health-related quality of life among patients with chronic obstructive pulmonary disease. Iran J Public Health. 2017;46(8):1046.PubMedPubMedCentral Garcia-Gordillo MA, Collado-Mateo D, Olivares PR, Adsuar JC, Merellano-Navarro E. A cross-sectional assessment of health-related quality of life among patients with chronic obstructive pulmonary disease. Iran J Public Health. 2017;46(8):1046.PubMedPubMedCentral
3.
go back to reference Halbert R, Natoli J, Gano A, Badamgarav E, Buist AS, Mannino D. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–32.CrossRef Halbert R, Natoli J, Gano A, Badamgarav E, Buist AS, Mannino D. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–32.CrossRef
4.
go back to reference Melville A, Pless-Mulloli T, Afolabi O, Stenton S. COPD prevalence and its association with occupational exposures in a general population. Eur Respir J. 2010;36(3):488–93.CrossRef Melville A, Pless-Mulloli T, Afolabi O, Stenton S. COPD prevalence and its association with occupational exposures in a general population. Eur Respir J. 2010;36(3):488–93.CrossRef
5.
go back to reference Doucet M, Rochette L, Hamel D. Incidence, prevalence, and mortality trends in chronic obstructive pulmonary disease over 2001 to 2011: a public health point of view of the burden. Can Respir J. 2016;2016:7518287.CrossRef Doucet M, Rochette L, Hamel D. Incidence, prevalence, and mortality trends in chronic obstructive pulmonary disease over 2001 to 2011: a public health point of view of the burden. Can Respir J. 2016;2016:7518287.CrossRef
6.
go back to reference Maleki-Yazdi MR, Kelly SM, Lam SS, Marin M, Barbeau M, Walker V. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J. 2012;19(5):319–24.CrossRef Maleki-Yazdi MR, Kelly SM, Lam SS, Marin M, Barbeau M, Walker V. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J. 2012;19(5):319–24.CrossRef
7.
go back to reference Dang-Tan T, Zhang S, Tavares RV, Stutz M, Ismaila AS, Vaillancourt J, et al. The burden of illness related to chronic obstructive pulmonary disease exacerbations in Québec, Canada. Can Respir J. 2017;2017:8184915.PubMedPubMedCentral Dang-Tan T, Zhang S, Tavares RV, Stutz M, Ismaila AS, Vaillancourt J, et al. The burden of illness related to chronic obstructive pulmonary disease exacerbations in Québec, Canada. Can Respir J. 2017;2017:8184915.PubMedPubMedCentral
8.
go back to reference Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. East Mediterr Health J. 2019;25(1):47–57.CrossRef Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. East Mediterr Health J. 2019;25(1):47–57.CrossRef
9.
go back to reference Sharifi H, Ghanei M, Jamaati H, Masjedi MR, Aarabi M, Sharifpour A, et al. Burden of obstructive lung disease in Iran: Prevalence and risk factors for COPD in North of Iran. Int J Prev Med. 2020;11:78.CrossRef Sharifi H, Ghanei M, Jamaati H, Masjedi MR, Aarabi M, Sharifpour A, et al. Burden of obstructive lung disease in Iran: Prevalence and risk factors for COPD in North of Iran. Int J Prev Med. 2020;11:78.CrossRef
10.
go back to reference Sharifi H, Masjedi MR, Emami H, Ghanei M, Eslaminejad A, Radmand G, et al. Burden of obstructive lung disease study in Tehran: prevalence and risk factors of chronic obstructive pulmonary disease. Lung India J. 2015;32(6):572.CrossRef Sharifi H, Masjedi MR, Emami H, Ghanei M, Eslaminejad A, Radmand G, et al. Burden of obstructive lung disease study in Tehran: prevalence and risk factors of chronic obstructive pulmonary disease. Lung India J. 2015;32(6):572.CrossRef
11.
go back to reference Amra B, Golshan M, Fietze I, Penzel T, Welte T. Correlation between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome in a general population in Iran. J Res Med Sci. 2011;16(7):885.PubMedPubMedCentral Amra B, Golshan M, Fietze I, Penzel T, Welte T. Correlation between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome in a general population in Iran. J Res Med Sci. 2011;16(7):885.PubMedPubMedCentral
12.
go back to reference Sharifi H, Ghanei M, Jamaati H, Masjedi MR, Aarabi M, Sharifpour A, et al. Burden of obstructive lung disease study in Iran: first report of the prevalence and risk factors of COPD in five provinces. Lung India J. 2019;36(1):14.CrossRef Sharifi H, Ghanei M, Jamaati H, Masjedi MR, Aarabi M, Sharifpour A, et al. Burden of obstructive lung disease study in Iran: first report of the prevalence and risk factors of COPD in five provinces. Lung India J. 2019;36(1):14.CrossRef
13.
go back to reference Varmaghani M, Farzadfar F, Sharifi F, Rashidain A, Moin M, Moradi-Lakeh M, et al. prevalence of asthma, COPD, and chronic bronchitis in Iran: A systematic review and meta-analysis. Iran J Allergy Asthma Immunol. 2016;15(2):93.PubMed Varmaghani M, Farzadfar F, Sharifi F, Rashidain A, Moin M, Moradi-Lakeh M, et al. prevalence of asthma, COPD, and chronic bronchitis in Iran: A systematic review and meta-analysis. Iran J Allergy Asthma Immunol. 2016;15(2):93.PubMed
14.
go back to reference Horner A, Soriano JB, Puhan MA, Studnicka M, Kaiser B, Vanfleteren LE, et al. Altitude and COPD prevalence: analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. Respir Res. 2017;18(1):162.CrossRef Horner A, Soriano JB, Puhan MA, Studnicka M, Kaiser B, Vanfleteren LE, et al. Altitude and COPD prevalence: analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. Respir Res. 2017;18(1):162.CrossRef
15.
go back to reference Jaganath D, Miranda JJ, Gilman RH, Wise RA, Diette GB, Miele CH, et al. prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru. Respir Res. 2015;16(1):40.CrossRef Jaganath D, Miranda JJ, Gilman RH, Wise RA, Diette GB, Miele CH, et al. prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru. Respir Res. 2015;16(1):40.CrossRef
16.
go back to reference Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343–9.CrossRef Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343–9.CrossRef
17.
go back to reference Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, et al. Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study): rationale, objectives, and design. Am J Epidemiol. 2018;187(4):647–55.CrossRef Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, et al. Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study): rationale, objectives, and design. Am J Epidemiol. 2018;187(4):647–55.CrossRef
18.
go back to reference Khaledifar A, Hashemzadeh M, Solati K, Poustchi H, Bollati V, Ahmadi A, et al. The protocol of a population-based prospective cohort study in southwest of Iran to analyze common non-communicable diseases: Shahrekord cohort study. BMC Public Health. 2018;18(1):660.CrossRef Khaledifar A, Hashemzadeh M, Solati K, Poustchi H, Bollati V, Ahmadi A, et al. The protocol of a population-based prospective cohort study in southwest of Iran to analyze common non-communicable diseases: Shahrekord cohort study. BMC Public Health. 2018;18(1):660.CrossRef
19.
go back to reference Ghobadi H, Ahari SS, Kameli A, Lari SM. The relationship between COPD assessment test (CAT) scores and severity of airflow obstruction in stable COPD patients. Tanaffos. 2012;11(2):22–6.PubMedPubMedCentral Ghobadi H, Ahari SS, Kameli A, Lari SM. The relationship between COPD assessment test (CAT) scores and severity of airflow obstruction in stable COPD patients. Tanaffos. 2012;11(2):22–6.PubMedPubMedCentral
20.
go back to reference Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–81.CrossRef Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–81.CrossRef
21.
go back to reference Kiani FZ, Ahmadi A. Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran. Sci Rep. 2021;11:1548.CrossRef Kiani FZ, Ahmadi A. Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran. Sci Rep. 2021;11:1548.CrossRef
22.
go back to reference Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–82.CrossRef Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–82.CrossRef
23.
go back to reference Hoesein FAM, Zanen P, Lammers J-WJ. Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review. Respir Med. 2011;105(6):907–15.CrossRef Hoesein FAM, Zanen P, Lammers J-WJ. Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review. Respir Med. 2011;105(6):907–15.CrossRef
24.
go back to reference Hardie J, Buist AS, Vollmer W, Ellingsen I, Bakke P, Mørkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117–22.CrossRef Hardie J, Buist AS, Vollmer W, Ellingsen I, Bakke P, Mørkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117–22.CrossRef
25.
go back to reference Hansen JE, Sun X-G, Wasserman K. Spirometric criteria for airway obstruction: use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest. 2007;131(2):349–55.CrossRef Hansen JE, Sun X-G, Wasserman K. Spirometric criteria for airway obstruction: use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest. 2007;131(2):349–55.CrossRef
26.
go back to reference Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.CrossRef Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.CrossRef
27.
go back to reference Quanjer PH, Pretto JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: new wine in new bottles. Eur Respir J. 2013;43(2):505–12.CrossRef Quanjer PH, Pretto JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: new wine in new bottles. Eur Respir J. 2013;43(2):505–12.CrossRef
28.
go back to reference Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716–23.CrossRef Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716–23.CrossRef
29.
go back to reference Bourbeau J, Tan WC, Benedetti A, Aaron SD, Chapman KR, Coxson HO, et al. Canadian Cohort Obstructive Lung Disease (CanCOLD): fulfilling the need for longitudinal observational studies in COPD. COPD. 2014;11(2):125–32.CrossRef Bourbeau J, Tan WC, Benedetti A, Aaron SD, Chapman KR, Coxson HO, et al. Canadian Cohort Obstructive Lung Disease (CanCOLD): fulfilling the need for longitudinal observational studies in COPD. COPD. 2014;11(2):125–32.CrossRef
30.
go back to reference Adab P, Fitzmaurice D, Dickens A, Ayres J, Buni H, Cooper B, et al. Cohort profile: The Birmingham Chronic Obstructive Pulmonary Disease (COPD) cohort study. Int J Epidemiol. 2016;46(1):23–23. Adab P, Fitzmaurice D, Dickens A, Ayres J, Buni H, Cooper B, et al. Cohort profile: The Birmingham Chronic Obstructive Pulmonary Disease (COPD) cohort study. Int J Epidemiol. 2016;46(1):23–23.
31.
go back to reference Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9(1):871–88.CrossRef Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9(1):871–88.CrossRef
32.
go back to reference Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir Investig. 2016;54(6):387–96.CrossRef Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir Investig. 2016;54(6):387–96.CrossRef
33.
go back to reference Gebreyes YF, Goshu DY, Geletew TK, Argefa TG, Zemedu TG, Lemu KA, et al. prevalence of high bloodpressure, hyperglycemia, dyslipidemia, metabolic syndrome and their determinants in Ethiopia: evidences from the National NCDs STEPS Survey, 2015. PLoS ONE. 2018;13(5):e0194819.CrossRef Gebreyes YF, Goshu DY, Geletew TK, Argefa TG, Zemedu TG, Lemu KA, et al. prevalence of high bloodpressure, hyperglycemia, dyslipidemia, metabolic syndrome and their determinants in Ethiopia: evidences from the National NCDs STEPS Survey, 2015. PLoS ONE. 2018;13(5):e0194819.CrossRef
34.
go back to reference Yin H-L, Yin S-Q, Lin Q-Y, Xu Y, Xu H-W, Liu T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: a meta-analysis. Medicine. 2017;96(19):e6836.CrossRef Yin H-L, Yin S-Q, Lin Q-Y, Xu Y, Xu H-W, Liu T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: a meta-analysis. Medicine. 2017;96(19):e6836.CrossRef
Metadata
Title
Profile and preliminary results of Iranian sub cohort chronic obstructive pulmonary disease (COPD) in Shahrekord PERSIAN cohort in southwest Iran
Authors
Fatemeh Zeynab Kiani
Ali Ahmadi
Akbar Soleymani Babadi
Hamid Rouhi
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01469-8

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.